Loading...
GNFT.Y logo

Genfit S.A.Informe acción OTCPK:GNFT.Y

Capitalización bursátil US$541.3m
Precio de las acciones
US$8.95
US$12.86
30.4% infravalorado descuento intrínseco
1Y146.6%
7D-0.8%
1D
Valor de la cartera
​
Ver

Genfit S.A.

Informe acción OTCPK:GNFT.Y

Capitalización de mercado: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit (GNFT.Y) Resumen de Acciones

Genfit S.A., empresa biofarmacéutica en fase avanzada, descubre y desarrolla fármacos candidatos y soluciones diagnósticas para enfermedades metabólicas y hepáticas. Saber más

Análisis fundamental de GNFT.Y
Puntuación del snowflake
Valoración1/6
Crecimiento futuro4/6
Rendimiento pasado0/6
Salud financiera4/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 25.5%

Análisis de riesgos

Precio de las acciones volátil durante los últimos 3 meses en comparación con el mercado US


GNFT.Y Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Genfit S.A.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Genfit
Precios históricos de las acciones
Precio actual de la acción€8.95
Máximo en las últimas 52 semanas€10.20
Mínimo de 52 semanas€2.55
Beta1.19
Cambio en 1 mes24.48%
Variación en 3 meses52.73%
Cambio de 1 año146.56%
Variación en 3 años116.71%
Variación en 5 años86.46%
Variación desde la OPV-59.63%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

Rentabilidad de los accionistas

GNFT.YUS BiotechsMercado US
7D-0.8%1.2%1.1%
1Y146.6%34.6%28.7%

Rentabilidad vs. Industria: GNFT.Y superó a la industria US Biotechs, que obtuvo un rendimiento del 34.6% el año pasado.

Rentabilidad vs. Mercado: GNFT.Y superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.

Volatilidad de los precios

Is GNFT.Y's price volatile compared to industry and market?
GNFT.Y volatility
GNFT.Y Average Weekly Movement11.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de GNFT.Y ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GNFT.Y(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
1999188M. Prigentwww.genfit.com

Genfit S.A., empresa biofarmacéutica en fase avanzada, descubre y desarrolla fármacos candidatos y soluciones diagnósticas para enfermedades metabólicas y hepáticas. La empresa desarrolla Elafibranor, que está en fase III de ensayo clínico para tratar a pacientes con colangitis biliar primaria. También se dedica al desarrollo de la tecnología NIS4 para el diagnóstico de la esteatohepatitis no alcohólica (NASH) y la fibrosis; VS-01 para el tratamiento del trastorno del ciclo de la urea (UCD) y el trastorno de la acidemia orgánica (OAD); GNS561, que está en ensayo de fase 1b/2a para tratar a pacientes con colangiocarcinoma (CCA); VS-01-ACLF y Nitazoxanida (NTZ), que está en fase 1 de ensayo para tratar la insuficiencia hepática aguda-crónica, así como VS-02-HE, que está en ensayo preclínico para el tratamiento de la Reducción de la Hiperamonemia y la Estabilización del Amoníaco en Sangre; CML-022; SRT-015, un inhibidor de ASK1 dirigido a la inhibición de la apoptosis celular, la inflamación y la fibrosis.

Resumen de fundamentos de Genfit S.A.

¿Cómo se comparan los beneficios e ingresos de Genfit con su capitalización de mercado?
Estadísticas fundamentales de GNFT.Y
Capitalización bursátilUS$541.33m
Beneficios(TTM)-US$45.02m
Ingresos (TTM)US$52.41m
10.3x
Ratio precio-ventas (PS)
-12.0x
Ratio precio-beneficio (PE)

¿Está GNFT.Y sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GNFT.Y
Ingresos€45.13m
Coste de los ingresos€0
Beneficio bruto€45.13m
Otros gastos€83.89m
Beneficios-€38.76m

Últimos beneficios comunicados

Jun 30, 2025

Próxima fecha de beneficios

Apr 02, 2026

Beneficios por acción (BPA)-0.78
Margen bruto100.00%
Margen de beneficio neto-85.89%
Ratio deuda/patrimonio255.9%

¿Cómo se ha desempeñado GNFT.Y a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/03/11 19:47
Precio de las acciones al final del día2026/03/09 00:00
Beneficios2025/06/30
Ingresos anuales2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Genfit S.A. está cubierta por 14 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank